Mechanistic Drivers for Potent Pharmacodynamic Activity of Verekitug, a novel anti-TSLPR antibody - Amsterdam 2025

Recent advances in our mechanistic understanding of airways disease to facilitate superior patient stratification and treatment

Chair(s): Robert Snelgrove, Cecilia K. Andersson

Session type: Oral presentation

Mechanistic Drivers for Potent Pharmacodynamic Activity of Verekitug, a novel anti-TSLPR antibody

Fatema Chowdhury

EVENTS HOME

Previous presentation

Next presentation

Session content

Molecular differences in asthma burden identified through multi-omics integration

Nazanin Zounemat-kermani

Replay

Poster

Abstract

Slides

Sex differences in asthma: multi-omic analysis using U-BIOPRED data

Jiashu Shen

Replay

Poster

Abstract

Slides

Inflammatory Protein Biomarkers in COPD Subjects with and without Alpha-1 Antitrypsin Deficiency

Matthew Moll

Replay

Poster

Abstract

Slides

C24:1 ceramide alleviates neutrophilic asthma by modulating Th17 differentiation via the EP2-JAK2-STAT3 pathway

Huan Liu

Replay

Poster

Abstract

Slides

Role of Tricellulin on Bronchial Epithelial Barrier in Asthma

Xin Yao

Replay

Abstract

Slides

Late Breaking Abstract - Early life phthalate exposure promotes skin barrier dysfunction and associated allergic airway disease

Debajyoti Ghosh

Replay

Poster

Abstract

Slides

ASM promotes macrophage glycolysis and M1 polarization by activating the mTOR/HIF-1? pathway in neutrophilic asthma

Huan Liu

Replay

Poster

Abstract

Slides

The Impact of Salmeterol and Fluticasone on Clinical Outcomes and Inflammatory Mediators in Asthma in vivo

Eva Fiorenzo

Replay

Poster

Abstract

Slides

TSLPR-expressing Cell Profiling in Airway and Blood Samples from Severe Asthma Patients

Naoya Fujino

Replay

Poster

Abstract

Slides

Mechanistic Drivers for Potent Pharmacodynamic Activity of Verekitug, a novel anti-TSLPR antibody

Fatema Chowdhury

Replay

Poster

Abstract

Discussion and Q&A

CDN Connection Issue

The ERS Congress 2025, Amsterdam

#{title}